Molecular mechanisms of drug influx and efflux transport at the blood-brain barrier

Folia Pharmacologica Japonica

Volumn 122, Issue 1, 2003, Pages 55-64

  Ohtsuki, Sumio ^a   Hori, Satoko ^a   Terasaki, Tetsuya ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Blood brain barrier; Brain capillary endothelial cells; Efflux transport; Influx transport; Transporter

Indexed keywords

ABC TRANSPORTER; ACICLOVIR; ADENOSINE TRIPHOSPHATE; AMINO ACID TRANSPORTER; BACLOFEN; BENZOIC ACID DERIVATIVE; CEFAZOLIN; DRUG METABOLITE; HOMOVANILLIC ACID; KETOPROFEN; LEVODOPA; MERCAPTOPURINE; MU OPIATE RECEPTOR AGONIST; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 3; UNCLASSIFIED DRUG; VALPROIC ACID;

BLOOD BRAIN BARRIER; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TRANSPORT; ENDOCYTOSIS; ENERGY; INTERSTITIAL FLUID; LIPOPHILICITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

AMINO ACID TRANSPORT SYSTEM L; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM; DRUG DESIGN; ENDOCYTOSIS; ENDOTHELIUM, VASCULAR; HUMANS; MEMBRANE TRANSPORT PROTEINS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PHARMACOKINETICS;

EID: 0038268754     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.122.55     Document Type: Review

References (50)

1. Hosoya K, Ohtsuki S, Terasaki T. Recent advances in the brain-to-blood efflux transport across the blood-brain barrier. Int J Pharm. 2002;248:15-29.
2. Pardridge WM. Introduction to the blood-brain barrier. Cambridge University Press. Cambridge. 1998.
3. Farrell CL, Pardridge WM. Ultrastructural localization of blood-brain barrier-specific antibodies using immunogold-silver enhancement techniques. J Neurosci Methods. 1991;37:103-110.
4. Bell GI, Burant CF, Takeda J, Gould GW. Structure and function of mammalian facilitative sugar transporters. J Biol Chem. 1993;268:19161-19164.
5. Agus DB, Gambhir SS, Pardridge WM, et al. Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J Clin Invest. 1997;100:2842-2848.
6. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 1998;273:23629-23632.
7. Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM. Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc Natl Acad Sci USA. 1999;96:12079-12084.
8. Abbott NJ, Romero IA. Transporting therapeutics across the blood-brain barrier. Mol Med Today. 1996;2:106-113.
9. Gomes P, Soares-da-Silva P. L-DOPA transport properties in an immortalised cell line of rat capillary cerebral endothelial cells, RBE 4. Brain Res. 1999;829:143-150.
10. Pincus JH, Barry K. Protein redistribution diet restores motor function in patients with dopa-resistant "off" periods. Neurology. 1988;38:481-483.
11. 1-specific opioid peptide, H-Tyr-D-Arg-Phe-β-Ala-OH (TAPA). J Neurochem. 2003;84:1154-1161.
12. Hosoya K, Tetsuka K, Nagase K, et al. Conditionally immortalized brain capillary endothelial cell lines established from a transgenic mouse harboring temperature-sensitive simian virus 40 large T-antigen gene. AAPS PharmSci. 2000;2:E27.
13. Tanabe S, Shimohigashi Y, Nakayama Y, et al. In vivo and in vitro evidence of blood-brain barrier transport of a novel cationic arginine-vasopressin fragment 4-9 analog. J Pharmacol Exp Ther. 1999;290:561-568.
14. Terasaki T, Hirai K, Sato H, Kang YS, Tsuji A. Absorptive-mediated endocytosis of a dynorphin-like analgesic peptide, E-2078 into the blood-brain barrier. J Pharmacol Exp Ther. 1989;251:351-357.
15. Kumagai AK, Eisenberg JB, Pardridge WM. Absorptive-mediated endocytosis of cationized albumin and a β-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. J Biol Chem. 1987;262:15214-15219.
16. 125I] transferrin through the rat blood-brain barrier. Brain Res. 1995;683:164-171.
17. Pardridge WM, Kang YS, Buciak JL, Yang J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm Res. 1995;12:807-816.
18. Shi N, Pardridge WM. Noninvasive gene targeting to the brain. Proc Natl Acad Sci USA. 2000;97:7567-7572.
19. Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdrl (P-glycoprotein) gene from multidrug-resistant human cells. Cell. 1986;47:381-389.
20. Tsuji A, Terasaki T, Takabatake Y, et al. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci. 1992;51:1427-1437.
21. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77:491-502.
22. Liu R, Sharom FJ. Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains. Biochemistry. 1996;35:11865-11873.
23. Panzenboeck U, Balazs Z, Sovic A, et al. ABCA1 and scavenger receptor class B, type I, are modulators of reverse sterol transport at an in vitro blood-brain barrier constituted of porcine brain capillary endothelial cells. J Biol Chem. 2002;277:42781-42789.
24. Eisenblatter T, Galla HJ. A new multidrug resistance protein at the blood-brain barrier. Biochem Biophys Res Commun. 2002;293:1273-1278.
25. Zhang Y, Han H, Elmquist WF, Miller DW. Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res. 2000;876:148-153.
26. Cooray HC, Blackmore CG, Maskell L, Barrand MA. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport. 2002;13:2059-2063.
27. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, Sarkadi B. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001;285:111-117.
28. Lawn RM, Wade DP, Garvin MR, et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest. 1999;104:R25-31.
29. Emanuelsson BM, Paalzow L, Sunzel M. Probenecid-induced accumulation of 5-hydroxyindoleacetic acid and homovanillic acid in rat brain. J Pharm Pharmacol. 1987;39:705-710.
30. Mori S, Takanaga H, Ohtsuki S, Kang YS, Hosoya K, Terasaki T. Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. J Cereb Blood Flow Metab. 2003;23:432-440.
31. Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K, Terasaki T. Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. J Neurochem. 2002;83:57-66.
32. Deguchi T, Ohtsuki S, Otagiri M, et al. Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney. Kidney Int. 2002;61:1760-1768.
33. Deguchi Y, Yokoyama Y, Sakamoto T, et al. Brain distribution of 6-mercaptopurine is regulated by the efflux transport system in the blood-brain barrier. Life Sci. 2000;66:649-662.
34. Almond MK, Fan S, Dhillon S, Pollock AM, Raftery MJ. Avoiding acyclovir neurotoxicity in patients with chronic renal failure undergoing haemodialysis. Nephron. 1995;69:428-432.
35. Nakada Y, Yamamoto K, Kawakami J, Sawada Y, Iga T. Effect of acute renal failure on neurotoxicity of cimetidine in rats. Pharm Res. 1995;12:1953-1957.
36. Schliamser SE, Cars O, Norrby SR. Neurotoxicity of β-lactam antibiotics: predisposing factors and pathogenesis. J Antimicrob Chemother. 1991;27:405-425.
37. Kakee A, Takanaga H, Hosoya K, Sugiyama Y, Terasaki T. In vivo evidence for brain-to-blood efflux transport of valproic acid across the blood-brain barrier. Microvasc Res. 2002;63:233-238.
38. Morrison PF, Morishige GM, Beagles KE, Heyes MP. Quinolinic acid is extruded from the brain by a probenecid-sensitive carrier system: a quantitative analysis. J Neurochem. 1999;72:2135-2144.
39. Stone TW. Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Prog Neurobiol. 2001;64:185-218.
40. Kakee A, Takanaga H, Terasaki T, Naito M, Tsuruo T, Sugiyama Y. Efflux of a suppressive neurotransmitter, GABA, across the blood-brain barrier. J Neurochem. 2001;79:110-118.
41. Takanaga H, Ohtsuki S, Hosoya K, Terasaki T. GAT2/BGT-1 as a system responsible for the transport of γ-aminobutyric acid at the mouse blood-brain barrier. J Cereb Blood Flow Metab. 2001;21:1232-1239.
42. Hosoya K, Sugawara M, Asaba H, Terasaki T. Blood-brain barrier produces significant efflux of L-aspartic acid but not D-aspartic acid: in vivo evidence using the brain efflux index method. J Neurochem. 1999;73:1206-1211.
43. Hardebo JE, Owman C. Characterization of the in vitro uptake of monoamines into brain microvessels. Acta Physiol Scand. 1980;108:223-229.
44. Wakayama K, Ohtsuki S, Takanaga H, Hosoya K, Terasaki T. Localization of norepinephrine and serotonin transporter in mouse brain capillary endothelial cells. Neurosci Res. 2002;44:173-180.
45. Cohen Z, Bonvento G, Lacombe P, Hamel E. Serotonin in the regulation of brain microcirculation. Prog Neurobiol. 1996;50:335-362.
46. Pardridge WM. Drug and gene delivery to the brain: the vascular route. Neuron. 2002;36:555-558.
47. Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci. 2000;89:1371-1388.
48. Tsuji A, Tamai I. Blood-brain barrier transport of drugs. In: Pardridge WM, editors. Introduction to the blood-brain barrier. Cambridge: Cambridge University Press; 1998. p. 238-247.
49. Hagenbuch B, Gao B, Meier PJ. Transport of xenobiotics across the blood-brain barrier. News Physiol Sci. 2002;17:231-234.